Metabolomic and BH3 profiling of esophageal cancers: novel assessment methods for precision therapy

[1]  P. Khong,et al.  PET/CT in the evaluation of treatment response to neoadjuvant chemoradiotherapy and prognostication in patients with locally advanced esophageal squamous cell carcinoma , 2016, Nuclear medicine communications.

[2]  Laurence E Court,et al.  The Incremental Value of Subjective and Quantitative Assessment of 18F-FDG PET for the Prediction of Pathologic Complete Response to Preoperative Chemoradiotherapy in Esophageal Cancer , 2016, The Journal of Nuclear Medicine.

[3]  A. McKenna,et al.  Paired Exome Analysis of Barrett’s Esophagus and Adenocarcinoma , 2015, Nature Genetics.

[4]  Karen Cichowski,et al.  Drug-Induced Death Signaling Strategy Rapidly Predicts Cancer Response to Chemotherapy , 2015, Cell.

[5]  J. Reynolds,et al.  Value of CT–PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma , 2014, The British journal of surgery.

[6]  A. Ba-Ssalamah,et al.  The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. , 2014, The Journal of thoracic and cardiovascular surgery.

[7]  A. Hölscher,et al.  Prognostic Classification of Histopathologic Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma , 2014, Annals of surgery.

[8]  Fredrik Mattsson,et al.  Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Karen H. Vousden,et al.  Mutant p53 in Cancer: New Functions and Therapeutic Opportunities , 2014, Cancer cell.

[10]  C. Mariette,et al.  Is There a Role for Surgery for Patients with a Complete Clinical Response after Chemoradiation for Esophageal Cancer? An Intention-to-Treat Case-Control Study , 2013, Annals of surgery.

[11]  J. Ajani,et al.  Association between clinical complete response and pathological complete response after preoperative chemoradiation in patients with gastroesophageal cancer: analysis in a large cohort. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  E W Steyerberg,et al.  Preoperative chemoradiotherapy for esophageal or junctional cancer. , 2012, The New England journal of medicine.

[13]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[14]  J. Reynolds,et al.  Cancer Cachexia: Mechanisms and Clinical Implications , 2011, Gastroenterology research and practice.

[15]  X. Yao,et al.  Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine , 2011, Prostate Cancer and Prostatic Diseases.

[16]  N. Bellance,et al.  Metabolomics for mitochondrial and cancer studies. , 2011, Biochimica et biophysica acta.

[17]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[18]  A. Letai,et al.  Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes , 2010, Proceedings of the National Academy of Sciences.

[19]  A. Casson,et al.  Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[20]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[21]  John T. Wei,et al.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression , 2009, Nature.

[22]  S. Eckhardt,et al.  Clinical Applications of Metabolomics in Oncology: A Review , 2009, Clinical Cancer Research.

[23]  E. Morselli,et al.  Targeting p53 to mitochondria for cancer therapy , 2008, Cell cycle.

[24]  R. Munden,et al.  Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[26]  Hao Wang,et al.  Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Jeffrey S. Morris,et al.  Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation , 2005, Cancer.

[28]  J. Lee,et al.  A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  A. Letai,et al.  To Prime, or Not to Prime: That Is the Question. , 2016, Cold Spring Harbor symposia on quantitative biology.

[30]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[31]  H. Cooper,et al.  Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. , 2015, The Annals of thoracic surgery.

[32]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[33]  M. Kris,et al.  Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. , 2014, The Lancet. Oncology.

[34]  Trevor J Pugh,et al.  Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .

[35]  R. Munden,et al.  Detection of interval distant metastases , 2007, Cancer.

[36]  N. Dubrawsky.  Cancer statistics , 2022 .